Melphalan Ratiopharm (Melphalan Hydrochloride)

Melphalan hydrochloride acts as an alkylating agent that forms covalent cross‑links between DNA strands. These cross‑links block DNA replication and transcription, leading to cell‑cycle arrest and programmed cell death, especially in rapidly dividing cancer cells.

The dose of Melphalan Ratiopharm is individualized by the prescribing oncologist based on factors such as the specific cancer type, disease stage, patient body surface area, renal and hepatic function, and prior treatment history. No fixed dosing schedule can be provided without a medical prescription.

Melphalan is classified as contraindicated in pregnancy because it can cause fetal harm, including teratogenic effects and miscarriage. It is also not recommended during breastfeeding, as it may be excreted in milk and affect the infant. Women of child‑bearing potential should use effective contraception during treatment.

To order Melphalan Ratiopharm, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Both melphalan and cyclophosphamide belong to the nitrogen‑mustard class of alkylating agents, but melphalan is generally more potent and is often used for high‑risk or refractory malignancies like multiple myeloma. Cyclophosphamide has a broader safety margin and is frequently employed in combination regimens for a wider range of cancers.

Melphalan Ratiopharm should be stored at ambient temperature, below 25 °C, in its original packaging. The container should be kept away from moisture, direct sunlight, and sources of heat to maintain product stability.

Melphalan Ratiopharm is supplied as an injectable solution for intravenous infusion. Administration is performed by a qualified healthcare professional in a clinical setting, following the dosing schedule prescribed by the treating oncologist.

The most serious risks include severe myelosuppression leading to life‑threatening infections, secondary malignancies, pulmonary toxicity such as interstitial pneumonitis, and acute renal impairment. Patients should be monitored closely for signs of infection, respiratory distress, and changes in kidney function.

Melphalan should not be given to patients with known hypersensitivity to melphalan or other nitrogen‑mustard agents, those who are pregnant, or individuals with uncontrolled severe infections. Caution is also advised for patients with pre‑existing severe bone‑marrow suppression, significant renal or hepatic impairment, and those receiving live vaccines.